Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practical Management of Bispecific Antibodies in Multiple Myeloma.

JCO oncology practice·2026
Same author

Genomic features do not account for differences in multiple myeloma risk by ancestry.

Blood cancer discovery·2026
Same author

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis.

American journal of hematology·2026
Same author

A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients.

Blood cancer journal·2026
Same author

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Diagnosis Disclosure and Related Illness Experience in Patients With Multiple Myeloma and Precursor Plasma Cell Disorders.

Clinical lymphoma, myeloma & leukemia·2026

Related Experiment Video

Updated: Oct 23, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K

Targeting BCMA in Multiple Myeloma.

Carlyn Rose Tan1, Urvi A Shah2

  • 1Myeloma Service Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E 74th Street, New York, NY, 10021, USA. tanc4@mskcc.org.

Current Hematologic Malignancy Reports
|August 25, 2021
PubMed
Summary
This summary is machine-generated.

New therapies targeting BCMA, including antibody-drug conjugates and CAR T-cell therapies, show promise for multiple myeloma patients who progress on existing treatments. Research is ongoing to overcome resistance to these novel agents.

Keywords:
Antibody-drug conjugatesBCMABispecific antibody constructsCAR T cell therapyMultiple myeloma

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K

Related Experiment Videos

Last Updated: Oct 23, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Multiple myeloma (MM) treatment has advanced, yet many patients still experience disease progression.
  • Resistance to current therapies necessitates the development of novel treatment strategies.

Purpose of the Study:

  • To review current and emerging BCMA-targeting therapies for multiple myeloma.
  • To discuss antibody-drug conjugates (ADCs), bispecific antibodies, and CAR T-cell therapies.
  • To examine clinical data and resistance mechanisms associated with BCMA-targeted agents.

Main Methods:

  • Review of published clinical data for BCMA-targeting therapies.
  • Analysis of mechanisms of action for ADCs, bispecific antibodies, and CAR T-cells.
  • Evaluation of patient responses and side effect profiles.

Main Results:

  • Anti-BCMA ADCs and bispecific antibodies demonstrate significant efficacy in relapsed/refractory MM with manageable side effects.
  • Adoptive cellular therapy (CAR T-cells) has shown dramatic, durable responses in heavily pretreated MM patients.
  • BCMA-targeted therapies hold substantial potential for improving MM management.

Conclusions:

  • BCMA-targeting agents represent a promising frontier in multiple myeloma treatment.
  • Combination strategies integrating BCMA-targeted therapies with standard treatments are anticipated.
  • Ongoing research aims to address and overcome resistance to novel anti-BCMA therapies.